Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders

MILWAUKEE, June 2, 2026 /PRNewswire/ -- Ademi LLP is investigating Rallybio (Nasdaq: RLY) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Avenzo Therapeutics. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.